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1. Introduction
Bladder cancer is the seventh most prevalent cancer worldwide and the second most common
genitourinary malignancy. As such, it is a significant cause of morbidity and mortality.
Although 75% of patients present with non-muscle invasive bladder cancer (NMIBC) at initial
diagnosis and can be managed with transurethral resection (TUR), the remaining 25% show
muscle-invasive bladder cancer (MIBC) at presentation (Messing, et al., 1995). In spite of
improvements in surgical technique, survival rates and outcomes for patients with MIBC are
not good. Radical cystectomy is unsuccessful in approximately 50% of patients with MIBC,
and the 5-year overall survival rate after radical cystectomy for MIBC is only 40%-60%
(Ghoneim, et al., 1997; Stein, et al. 2001; Shariat et al., 2006 Koga et al., 2008).
For these reasons, peri-operative therapies, including neo-adjuvant and adjuvant chemother‐
apy, have become more prominent and have been investigated in many trials and studies
(Hussain, et al., 2003; Goethuys and Van Poppel, 2012). Unfortunately, the percentages of
patients receiving neo-adjuvant and adjuvant chemotherapy for locally advanced bladder
cancer (T2-T4a) are only 12% and 22%, respectively (Feifer et al., 2011). One reason for the low
treatment rate with these modalities is that some urologists do not prefer a conservative
treatment option or to engage in a surgical approach, while others do not collaborate easily
across disciplines. This paper will provide a clear, straightforward description of trends in
peri-operative therapy for bladder cancer.
Organ conservation by combined modality therapy is commonplace in contemporary oncol‐
ogy and has achieved success in selected patients with various types of malignancies, such as
breast, larynx, esophagus, and prostate. However, radical cystectomy remains the most
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commonly offered treatment for bladder cancer; indeed, it is sometimes performed uncondi‐
tionally, even though this operation holds the possibility of significant morbidity. Modern
bladder conservation approaches combine surgery, chemotherapy, and radiation therapy.
However, there is variation in each protocol and in the methods used to carry out the protocols.
Over the last decade, numerous investigators have paid special attention to the multiple
interacting molecular pathways in urothelial cancer cells, and have demonstrated the complex
mechanisms of such interactions and their pathological roles in human bladder cancer.
Previous in vivo and in vitro studies have identified several factors as key to the development
and progression of urothelial cancer cells. In this paper, we highlight some of the major
molecular pathways and their clinical and pathological significance in bladder cancer. We also
present some molecular targeted agents and clinical trials in patients with MIBC.
2. Neo-adjuvant chemotherapy
One advantage of neo-adjuvant therapy compared with adjuvant therapy is that patient
tolerance is better; this is because the therapy is administered before surgery, including before
radical cystectomy. In addition, neo-adjuvant therapy allows for down-grading and down-
staging, which may increase the likelihood of resectability (Calabro and Sternberg, 2009).
Studies have shown that preoperative neo-adjuvant chemoradiation therapy reduced tumors
to the level of pT0 in approximately one quarter to one third of patients by the time cystectomy
was performed (Grossman et al., 2003; Alva et al., 2012). Such statistics give supporting
evidence to the possibility that bladder conservation therapy is a practical alternative for
selected patients with MIBC. This section will outline the history and present status of neo-
adjuvant therapy for patients with MIBC.
There have been several key randomized trials of radical cystectomy alone or with neo-
adjuvant therapy (Table 1). Among these trials, there has been no report of any single-agent
regimen producing a survival benefit through neo-adjuvant therapy (Wallance et al., 1991;
Martinez-Pineiro et al., 1995). A similar result was confirmed in a meta-analysis of individual
data from 2688 patients enrolled in 10 randomized trials (Advanced Bladder Cancer (ABC)
Meta-analysis Collaboration, 2003). On the other hand, there have been conflicting results on
the survival benefit of multi-agent chemotherapy. Among them, the Nordic Cystectomy Trial
I, performed using preoperative radiation therapy and 2 cycles of cisplatin (CDDP) and
doxorubicin (DXR) for patients with cT1G3-T4NxM0 disease, demonstrated no survival
benefit, either 5-year overall or cause-specific (Malmström et al., 1996). Similarly, the Nordic
Cystectomy Trial II (3 cycles of CDDP and methotrexate, MTX) showed no overall significant
difference in 5-year survival in 317 patients (Sherif et al., 2002). Thus, early trials revealed no
significant survival benefit of neo-adjuvant chemotherapy. Interestingly, however, the Nordic
Cystectomy Trial I also showed a 15% difference in overall survival for T3–T4a patients (P =
0.03). In addition, a combined analysis of the two Nordic Cystectomy Trials showed that the
5-year survival rates of patients receiving neo-adjuvant therapy (56%) were significantly better
(P = 0.049) compared with the patients not receiving neo-adjuvant therapy (48%) (Sherif, et al.,
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2004). These investigators concluded that neo-adjuvant platinum-based combination chemo‐
therapy was associated with a 20% reduction in the relative hazard of the probability of death.
In addition, a total of 449 patients form Nordic Cystectomy trial also showed that percentage
of pT0N0 was nearly double in the neo-adjuvant arm compared with controls (22.7% versus
12.5%, P = 0.006). Furthermore, there is a report that CDDP, MTX, and vinblastine (VBL)
showed more favorable results with neo-adjuvant chemotherapy compared with local therapy
alone without neo-adjuvant therapy (Medical Research Council, 1999). On the basis of
previously reported studies, one opinion is that neo-adjuvant chemotherapy cannot be
regarded as standard care (Kaufman et al., 2009). On the other hand, a trial with MVAC
(methotrexate, vinblastine, doxorubicin [adriamycin], and cisplatin) therapy showed a trend
toward a survival benefit with MVAC, although this difference did not reach the level of
significance (P = 0.06) (Grossman et al., 2003). Another prospective randomized trial by
Griffiths et al. (2011) showed that neo-adjuvant chemotherapy produced a survival benefit.
This study had a large impact because of the large study population (n = 976) and long follow-
up periods (median and interquartile range = 8.0 and 5.7 to 10.2 years). Thus, there are contrary
opinions regarding the survival benefit of neo-adjuvant chemotherapy for patients with MIBC.
However, a meta-analysis of 11 randomized trials conducted by the Advanced Bladder Cancer
Meta-analysis Collaboration that included 3005 bladder cancer patients demonstrated that
neo-adjuvant CDDP-based therapy had a significant positive effect on the absolute 5-year
overall survival rate (P = 0.003) and absolute disease-free survival rate (P < 0.0001) compared
with local therapy alone. A similar finding was reported in an additional meta-analysis
(Winquiest et al., 2004).
Authors (year) Intervention
Wallace 
(1991)
CDDP + Radiation therapy
Radiation therapy alone T2-4NxM0
No difference for overall survival (odds ratio=1.13 and
95% confidential interval=0.80-1.57)
Martinez
(1995)
CDDP+Cystectomy
Cystectomy alone
T2-4a
Nx-2M0 
pT0 was found in 14.3% of the experimental arm. 
No difference for cause-specific survival (P=0.1349).
Malmström
(1996)
CDDP+ADM+Cystectomy
Cystectomy alone
T1G3-
T4aNxM0
ND for overall survival (P=0.1) in T1-2
15% benefit in T3-4a
Sherif
(2002)
CDDP+MTX+Cystectomy
Cystectomy alone
T2-4a
NxM0
pT0 in experimental arm was higher (26.4%) than control 
arm (11.5%, P=0.001). No difference for overall survival
Sherif
(2004)
CDDP+ADM or CDDP+MTX
+Cystectomy vs Cystectomy
T1G3-
T4aNxM0
5-year overall survival rate were better (P=0.045) in 
experimental arm (56%) than that in control arm (48%). 
Grossman
(2003)
MVAC+Cystectomy
Cystectomy alone
T2-4a
NxM0
Pathological CR was higher in MVAC group (P<0.001).
Trends in benefit for overall survival (P=0.06) .
N
255
121
325
317
620
317
ICT
(2011)
CMV + definitive treatment
Definitive treatment alone
T2G3-
T4aN0/XM0
5-year overall survival rates were 49 versus 43% and 
10-year rates were 36 versus 30% (P=0.037). 976
ICT
(1999)
CMV + definitive treatment
Definitive treatment alone
T2G3-
T4aN0/XM0
3-year overall survival rates were 50.0% in chemotherapy 
arm versus 55.5% in no-chemotherapy arm (P=0.075). 
976
ICT: International Collaboration of Trialists
Clinical stage Comments
Table 1. Randomized studies for Neo-adjuvant therapy
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3. Adjuvant therapy
The advantage of adjuvant chemotherapy compared with neo-adjuvant chemotherapy is that
various clinical judgments can be made based on complete pathological information. This
avoids over-treatment and unnecessary adverse events because pathological staging enables
improved accuracy in patient selection for specific therapies. However, the anti-tumor effects
and survival benefits of adjuvant chemotherapy are controversial. Several randomized
prospective trials showed that adjuvant chemotherapy following cystectomy produced a
survival benefit (Skinner, et al., 1991; Stockle 1995). However, these reports are relatively old
(1990s) and underpowered (<100 patients). A study in 2010 by Paz et al. showed significantly
longer overall survival in patients receiving adjuvant chemotherapy than in patients without
adjuvant chemotherapy. Although this study had a relatively large number (n = 142), it was
closed early because of slow data accrual and un-published data. Other large and recent trials
(n > 100) have demonstrated that adjuvant chemotherapy following cystectomy did not show
a significant survival difference compared with cystectomy alone (Stadler, et al. 2011; Cognetti,
et al. 2012). Svatek (2010) conducted a large retrospective study on the relationship between
adjuvant therapy and survival, and showed that adjuvant therapy (n = 932, 23.6%) was
independently associated with favorable overall survival in 3947 bladder cancer patients.
As a result of such controversy, clinical trials on the survival benefit of adjuvant chemotherapy
are relatively underpowered because of the small number of patients and are closed early due
to poor data accrual. Another reason is the disadvantages of adjuvant chemotherapy, including
post-operative complications and decrease in renal function. Donat (2009) found that approx‐
imately 30% of patients who received radical cystectomy and were candidates for adjuvant
chemotherapy could not receive it within 90 days after operation. Thus, the role and aim of
adjuvant chemotherapy after radical cystectomy is not clear. We close our discussion of this
issue in the present paper because our main purposes are to discuss the prevention of cancer
cell dissemination and understand the processes in MIBC.
4. Bladder conservation strategy
Loss of bladder function is considered a major type of mutilation. Despite advances in neo-
bladder construction, a decrease in the quality of life (QOL) is inevitable after cystectomy. In
addition, although progress has occurred in peri-operative management, radical cystectomy
still has a high risk of complications, including peri-operative mortality (Manoharan, et al.,
2009). A recent large review (Shansigh, et al., 2009) of 1,142 patients showed that an early
complication (that is, within 90 days) occurred in 64% of patients undergoing radical cystec‐
tomy; 13% of the complications were classed as grade 3-5 by the modified Clavien grading
system. In recent years, multimodality bladder conservation strategies have gradually gained
popularity, and various investigations have been undertaken. In fact, an organ conservation
strategy is useful to preserve bladder function and QOL (Zietman, et al., 2003). A modern
bladder conservation strategy is the use of trimodality therapy, which combines maximal TUR
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followed by an induction course of concurrent radiotherapy and chemotherapy. Patients who
incompletely respond to the combined treatment are advised to undergo immediate cystec‐
tomy. However, at present, consensus has yet to be reached on the efficacy of bladder conser‐
vation therapy for the inhibition of cancer cell progression, and prolongation of survival has
yet to be reached (Herr, et al., 1998).
4.1. Present status of bladder conservation therapy
Appropriate candidates for bladder conservation therapy include: patients with T2-4a and
clinically node-negative disease, proposed complete or near-complete operation, and adequate
organ function to tolerate chemotherapy. Many urologists, medical oncologists, and radiation
oncologists have tried various protocols to decrease local recurrence and metastasis, and to
improve survival. In the beginning, various monotherapies were also investigated as a safe
method of treatment. However, several key studies from pioneer centers in the 1990s to 2000s
found that a combination of TUR, chemotherapy, and radiotherapy yielded more favorable
outcomes and better anti-tumor effects than monotherapies and other combination therapies
(Housset, 1993; Rodel, 2002; Shipley, 2002). At present, trimodality therapy is the major
treatment strategy for bladder preservation. In addition, with improvements in radiation
therapy and the development of chemotherapy, several trials have been performed in patients
with MIBC who are clinically node-positive (Röedel et al., 2002; Gamal El-deeen et al., 2009).
Furthermore, trials have also been performed in MIBC patients with multiple tumors (Zhang,
et al. 2010). Thus, the applications for bladder conservation therapy are expanding. Represen‐
tative reports on outcomes of bladder preservation therapies are shown in Table 2. This table
lists relatively large studies (over 100 patients) on trimodality therapy, as well as randomized
trials for patients with MIBC with/without lymph node metastasis. In addition to them, several
interesting and important studies have been reported. For example, the protocol that radiation
with combination chemotherapy of paclitaxel and CDDP chemotherapy was administrated
after TUR was reported in T2-T4a bladder cancer patients. In this protocol, if repeat biopsy
showed less than T1 disease, consolidation with similar chemo-radiation therapy was given.
If repeat biopsy showed greater than pT1 disease, cystectomy and adjuvant GC therapy were
given. Of the 80 eligible patients, 65 patients (81%) were judged complete response. However,
of these 65 patients, 8 patients (28%) had local bladder recurrence. At median follow-up of 49.4
months, the actuarial 5-year overall and cause-specific survival rate was 56% and 71%,
respectively. In addition, the actuarial rate of surviving with an intact bladder was 59% at 36
months and 47% at 60 months (Kaufman, et al. 2009). On the other hand, On the other hand,
most recently, a large study on long-term outcomes of bladder preservation by combined-
modality therapy for MIBC has also been reported from Massachusetts General Hospital
(Efstathiou et al., 2012). This study showed the outcomes in 348 patients with T2-4a disease
who were treated with CDDP-based chemotherapy and radiotherapy after maximal TUR plus
neo-adjuvant or adjuvant therapy. Survival analysis of median follow-up at 7.7 years demon‐
strated that 5-, 10-, and 15-year overall survival rates were 55%, 35%, and 22%, respectively.
On the other hand, the 5-, 10-, and 15-year cumulative bladder-intact disease-specific survival
rates were 60%, 45%, and 36%, respectively. These investigators also showed that 102 patients
(29%) required follow-up cystectomy. In the conclusion of their report, Efstathiou et al. stated
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their opinion that bladder conservation therapy offers a unique opportunity for urologic
surgeons, radiation oncologists, and medical oncologists to work together in a truly multidis‐
ciplinary effort for the benefit of patients with invasive bladder cancer. Likewise, we and many
other investigators have also suggested that the bladder conservation strategy is a useful and
practical alternative for patients who are selected appropriately and when clinical manage‐
ment includes the methods described below.
Author
(year) N Survival
Rödel
(2002)
Induction therapy
CDDP/CBDCA㼼5FU+RT
or RT alone
42415
BIS
OS: 50
CSS: 56
Perdoná
(2008)
CMV and RT
CMV and RT+CDDP
43
78
47
54
OS: 60
OS: 72
Consolidative
therapyRandom
No –
Weiss  
(2007) CDDP+5FU and RT112
61OS: 74
CSS: 82No –
–No
Gamal El-Deen
(2009)
MCV/MVAC/GC and RT
RT alone
114
72
–
–
OS: 60
OS: 68
–No
Zhang
(2010)
MVAC+RT: as adjuvant 
for pT3+4 or pN+100
OS: –
CSS: 68
No – –
–
5 years- (%)
Eapen
(2004) CDDP+RT112
OS: 50
CSS: –No
–
–
–
Sabba
(2010) GC and RT+CDDP104
OS: 55
CSS: –No –
–
–
Clinical
stage
T1-4NanyM0
T2-4N0M0
T1-4N0M0
T2-4aNanyM0
T2-4N0M0
Ta-4N0M0 
T2-3aN0M0
Route
IV
IV
IV
IV
IV
IA
IV
TUR
TUR
TUR
TUR
Partial
TUR
TUR
OS: Overall survival; CSS: Cause-specific survival, BIS: Bladder intact survival 
Shipley
(1998)
A: CMV and RT+CDDP
B: No chemotherapy
A: 61
B: 62
A: 38
B: 36
A: OS: 49
B: OS: 48
Kachnic
(1997) CMV and RT+CDDP106
43OS: 52
CSS: 60
RT+
CDDP
RT+
CDDP
No
YesT2-4aNxM0
T2-4aNxM0 IV
IV
TUR
TUR
Operation
Table 2. Published reports on bladder-conserving therapy (randomized study or patients number >100)
4.2. Intra-arterial chemotherapy in the bladder conservation strategy
Regarding the administration of chemotherapeutic drugs, intravenous infusion has been
common in almost all of the large studies (Table 2). On the other hand, intra-arterial chemo‐
therapy has also been used because infusion of chemotherapeutic drug(s) via the intra-arterial
route enables a higher drug concentration to be directed at the primary bladder tumor. This
treatment strategy, that is, the combination of intra-arterial chemotherapy and radiation
therapy, has been used in several studies. For example, Eapen, et al. (1989) reported intra-
arterial CDDP and concurrent radiation therapy with/without cystectomy in 25 bladder cancer
patients with T3-4N0M0 disease. Another example is that our own study group reported on a
combination therapy for 35 bladder cancer patients with T2-4N0M0, for whom two courses of
intra-arterial cisplatin and doxorubicin were administered at 3-week intervals, with radio‐
therapy administered for 4 weeks (Mokarim, et al., 1997). This study showed complete
response rates and tumor-free bladder preservation rates of 74% and 54%, respectively.
Unfortunately, these reports had relatively small numbers of patients (under 50 patients).
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At present, chemoradiation therapy incorporating this infusion protocol has resulted in high
complete remission (CR) rates of 83%-93% in patients with locally invasive bladder cancer
(Miyanaga, et al., 2000; Eapen, et al., 2004; Hashine et al., 2009). These rates seem to be higher
than the CR rates of conventional chemoradiation therapies, although a simple comparison is
impossible. However, these studies have also shown 5-year overall survival rates of 50%-66.6%
(Miyanaga, et al., 2000; Eapen, et al., 2004; Hashine, et al., 2009), which were similar to the
results of other studies using intravenous infusion (Table 2). Problems with this strategy
include specific complications (pelvic neuropathy and risk of severe bleeding) and the
complexity of the procedure. There has been only one report in a large study population on
trimodality bladder preservation incorporating intra-arterial chemotherapy (Eapen, et al.,
2004).
With regard to this treatment strategy, there has been a unique and interesting trial (Azuma,
et al., 2008) of combined therapy using balloon-occluded arterial infusion of CDDP and
hemodialysis with concurrent radiation. In this regimen, the study patients underwent TUR
and received balloon-occluded arterial infusion of 100-300 mg CDDP, together with concurrent
hemodialysis and a total of 60.4 Gy of radiation. In the first report, this therapy had been
administered to 41 patients with T2-4NxM0 disease. All patients with transitional cell carci‐
noma with T2-3 achieved a complete response (n = 29) and were able to retain their bladders
with no evidence of recurrence at a mean follow-up of 132 weeks (Azuma, et al., 2008).
4.3. Partial cystectomy in the bladder conservation strategy
With regard to surgery in bladder conservation therapy, TUR has been used in almost all of
the large studies (Table 2). On the other hand, several studies used partial cystectomy as the
primary therapy in their treatment strategy (Holzbeierlein et al., 2004; Kassouf et al., 2006;
Zhang et al., 2010). As mentioned above, radical cystectomy is the “gold standard” for surgical
treatment in patients with MIBC. In contrast, partial cystectomy provides a surgical alternative
for selected patients because patients who undergo partial cystectomy are considered to be at
higher risk for tumor recurrence and the need for second surgery (Evans and Texter, 1975;
Stein et al., 2001). Some authors hold the opinion that partial cystectomy is disproportionately
used and that overuse of this operation may constitute inappropriate delivery of health care
(Hollenbeck, et al., 2005). For these reasons, partial cystectomy is generally the recommended
treatment for adenocarcinoma and/or urothelial carcinoma at the dome of the urinary bladder.
However, there is no escaping the fact that partial cystectomy has potential advantages
compared with radical cystectomy, for example, functional advantages including continence
and sexual function, decreased incidence of surgical morbidity, and avoidance of the need for
urinary diversion. In recent years, population-based and matched case-control studies have
demonstrated that partial and radical cystectomy provided similar oncologic control and
outcome, including metastasis-free and cause-specific survival (Capitanio, et al., 2009;
Knoedler, et al., 2012). However, the fact remains that these results are obtained in “selected”
patients. In fact, two large cancer centers (Memorial Sloan-Kettering Cancer Center and M.D.
Anderson Cancer Center) have suggested that stringent selection of appropriate patients
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improves cancer control rates after partial cystectomy for patients with MIBC (Holzbeierlein,
et al., 2004; Kassouf, et al., 2006).
Ideal candidates for partial cystectomy are patients with a solitary tumor located in a resectable
area not requiring ureteral re-implantation, such as the dome of the urinary bladder, and which
can be resected with a 1-2 cm tumor-free margin to preserve normal bladder function. Patients
with associated carcinoma in situ should be excluded. Only 3%-10% of MIBC patients who are
candidates for cystectomy fit these criteria (Holzbeierlein, et al., 2004; Kassouf, et al., 2006;
Capitanio, et al., 2009). Marked variation in outcome after partial cystectomy has been
reported: the 5-year recurrence-free survival rates in separate series from M.D. Anderson
Cancer Center and Memorial Sloan-Kettering Cancer Center are 39% and 69%, respectively.
The bladder conservation strategy of partial cystectomy requires careful attention to patient
selection criteria in order to obtain optimal therapeutic outcome.
In recent years, laparoscopy with or without robotic radical cystectomy has begun to be
performed; this technique may lead to less bleeding, less post-operative pain, and earlier
recovery (Khan, et al., 2012). However, the long-term outcome is unclear, and the opera‐
tion requires a longer duration and engenders higher cost compared with open surgery.
These remain problems to be solved. Likewise, several studies and the experience of sev‐
eral  authors  with  robotic  partial  cystectomy  have  been  reported  (Luchey,  et  al.,  2012;
Seyam, et al., 2012). However, almost all of these procedures have been performed on be‐
nign tumors including paraganglioma and lymphangioma. On the other hand, there has
been  a  pilot  study  of  robotic  partial  cystectomy  for  bladder  cancer  (Allaparthi,  et  al.,
2010). Similar to radical cystectomy, obstacles to robotic partial cystectomy are high cost,
technical difficulties such as decisions regarding tumor margin, and relatively low num‐
bers  of  ideal  patients.  The  immediate  future  and  further  applications  of  robotic  partial
cystectomy for bladder cancer are uncertain.
5. GC regimen in peri-operative therapies
For the last several decades, MVAC and CMV (cisplatin, methotrexate, vinblastine) have been
especially employed for treating advanced urothelial carcinoma. Additionally, these regimens
have been used in almost all of the trials and studies on peri-operative chemotherapy. On the
other hand, the GC regimen has been reported as an alternative regimen and more tolerable
than the MVAC/CMV regimen in treating advanced urothelial cancer (von der Maase, et al.,
2005). In addition to treating advanced disease, the GC regimen seems more advantageous
than the MVAC/CMV regimen because the GC regimen has a lower toxicity profile and
therefore reduces the potential need for changing the treatment schedule because of toxic side
effects. Actually, various studies on peri-operative therapy with GC regimen have been
reported. In recent year, a randomized phase III trial of adjuvant GC therapy in 194 patients
with pT2G3-pT4N0-2 disease was reported. This manuscript demonstrated that 5-year overall
survival rate in adjuvant therapy (43.4%) was similar (P=0.24) to that in control (observation
and treatment on relapse) (53.7%).
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On the  other  hand,  several  studies  on  the  local  therapeutic  effects  of  neo-adjuvant  GC
therapy have been published (Table 3). In the series by Dash et al.,  pT0 was detected in
11 of 42 patients receiving the GC regimen (26%) and in 15 of 54 patients receiving the
MVAC regimen (28%). From these results, Dash et al. (2008) concluded that the GC regi‐
men has  ability  similar  to  that  of  the  MVAC regimen for  inducing  pathological  down-
staging in bladder cancer patients with locally advanced disease. Similar results (showing
complete response of MVAC = 31% and GC = 25%) were reported in 2012 by Yeshchina
et  al.  On the other  hand,  Weight,  et  al.  (2009)  reported that  the percentages of  patients
presenting  with  stage  pT0  at  the  time of  definitive  surgery  who were  treated  with  the
neo-adjuvant  GC regimen or  with  cystectomy alone were  10% (2/20)  and 9% (8/88),  re‐
spectively. In recent years, larger studies with a similar design showed that pT0 was de‐
tected in 20% (5 of 25) of patients with neo-adjuvant CG and 5% (7 of 135 patients) with
cystectomy alone (Scosyrev et  al.,  2011).  These authors  concluded that  the neo-adjuvant
GC regimen was capable of down-staging bladder cancer. Interestingly, Scosyrev et al. al‐
so suggested that GC has no effect on disease involving the lymph nodes. Unfortunately,
these studies were relatively small series and consisted of patients with a variety of clini‐
copathological  features.  Furthermore,  the  long-term  outcome  after  the  GC-  and  GEM-
based regimens for peri-operative treatment is still not fully known. Currently, in clinical
practice,  including phase  II  trials,  a  less  toxic  GC regimen is  commonly substituted for
peri-operative MVAC therapy.
Author
(year) N pT0 (%)  :  P value
Dash
(2008)
Induction
A:   42
B:   54
26
28
Scosyrev
(2012)
A: GC+radical cystectomy
B: Radical cystectomy only
A:   25
B: 135
20
5
Weight
(2009)
A:   20
B:   88
10
9
Clinical stage
T2-4N0M0
T2-4NanyM0
A: GC + cystectomy
B: MVAC + cystectomy
A: GC+radical cystectomy
B: Radical cystectomy only
Yeshchina
(2012)
A: GC + radical cystectomy
B: MAVC + radical cystectomy
A:   16
B:   45
25
31T2-4aN0-2M0 P=0.645
T2-4aN0-2M0
Capable of down-staging (proportion of 
pT0), but no effect on disease in node. 
This choice also affected no significant
difference in   adjuvant therapy (n=53).
P=0.03
No difference in down-staging, disease-
free survival, or residual disease.  . 
This study included 20 patients with GC 
(PTX in 1) and 9 with other regimens.   . 
–
–
Comments
Table 3. Neo-adjuvant gemcitabine plus cisplatin for muscle invasive bladder cancer
6. Molecular-targeted therapy
in peri-operative therapy
When molecular targeted therapy is performed, understanding of its clinical significance,
pathological roles, and prognostic value is essential. We therefore introduce some molecules
that are closely associated with malignant potential and aggressiveness in bladder cancer.
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6.1. p53
p53 regulates the cell cycle through inhibition of the cell cycle progression at the G1/S transi‐
tion, and p53 is also involved in various important cellular processes related to angiogenesis,
DNA repair, apoptosis, and response to therapy in bladder cancer cells (Mitra, et al., 2006).
The first report on the prognostic value of p53 expression in patients with bladder cancer
demonstrated that p53 expression status predicted recurrence and survival after radical
cystectomy in patients with organ-confined bladder cancer (Esrig, et al., 1994). After that, many
investigators showed that p53 mutations occur in approximately 50% of cases of bladder
cancer, and that altered p53 status is a useful predictor for cancer cell progression and outcome
in bladder cancer patients (Sarkis, et al. 1993; Esrig, et al., 1994; Serth, et al., 1995). However,
there was controversial opinion regarding the prognostic value of p53. Actually, a meta-
analysis that reviewed 117 studies with 10,026 patients showed that there is insufficient
evidence to know whether p53 can serve as a prognostic marker for bladder cancer (Malats,
et al., 2005).
Two independent clinical trials regarding p53 gene therapy were performed in a phase I study.
A study (SCH 58500) of the safety, feasibility, and biological activity of an adenoviral expres‐
sion vector encoding wild-type p53 was performed in 12 patients with histologically confirmed
Phase Sponsor Startyear
II
Intervention
CDDP, cabazitaxel 01616875United Bistrol Healthcare NHS Trust
Identifier
: NCT-
2012
I Intravesical vaccine(rF-GM-CSF, -TRICOM)
00072137University of Medicine and
Dentistry of New Jersey
2003
II IFM, DXR, GEM, CDDP 00080795M.D. Anderson Cancer Center 2001
On
going
II GEM, CDDP, Sunitinib 00847015MSKCC 2009 Yes
II Dose-dense MVAC 00808639Dana-Farber Cancer Institute 2008 Yes
II Dose-dense MVAC 01031420Fox Chase Cancer Center 2009 Yes
II GEM, CDDP, Sorafenib 01222676Fondazione IRCCS Istituto
Nazionale dei tumori
2010 Yes
II Erotinib 007498922008 YesM.D. Anderson Cancer Center
0 Lapatinib 01245660University Hospital, Bordeaux 2012 Yes
No
No
Yes
II CBDCA, GEM, ABI-007 00585689University of Michigan 2007 Yes
II MVAC, bevacizmab 005061552007 YesM.D. Anderson Cancer Center
II Dose-dense GC 01589094MSKCC 2012 Yes
II GEM, CDDP, Sunitinib 00859339Hoosier Oncology Group 2008 No
II Sunitinib after cystectomy
following prior neo-adjuvant
01042795University of Michigan 2009 Yes
Table 4. Clinical trials of neo-adjuvant therapies
Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment116
MIBC (Kuball, et al., 2002). In another study, replication-deficient adenoviral vectors bearing
the wild-type TP53 gene (Ad5CMV-TP53) were transferred into bladder cancer cells of
advanced disease by repeated (28-day cycle) intravesical instillation in 13 patients with locally
advanced disease (Pagliaro, et al., 2003). These studies showed that such methods are safe,
without no dose-limiting toxicity, and feasible for treatment of patients with bladder cancer.
Yet, although the use of gene therapy in combination with transduction-enhancing agents
increased transduction efficacy and promoted a high level of patient tolerance, some investi‐
gators believe that more improvements in the efficacy of gene transfer and greater knowledge
of gene expression levels are required to develop more effective gene therapy.
There is the opinion that locally advanced bladder cancer cells that harbor p53 alterations may
respond beneficially to adjuvant chemotherapy containing DNA-damaging agents (Cote, et
al., 1997). In addition, there have been several reports that DNA-damaging agents such as
CDDP can increase the sensitivity of the bladder cancer cell lines (Lai, et al., 2005; Matsui, et
al., 2007). Thus, gene therapy that targets p53 alterations has the possibility of being effective
for bladder cancer patients with advanced disease.
6.2. Epidermal Growth Factor Receptor (EGFR)
Among the members of the EGFR family, ErbB1 and ErbB2 (Her2/neu) are the most studied
in human cancers. There is general agreement that they are overexpressed in the majority of
patients with urothelial cancer of the urinary bladder, including MIBC, and are positively
associated with pathological features (Wright, et al., 1991; Korkolopoulou, et al., 1997, Kossouf,
et al., 2008). Furthermore, with regard to their predictive value for prognosis and survival,
increased expression of these two molecules has been reported to be associated with worse
outcome (Korkolopoulou, et al., 1997; Krüger, et al. 2002; Kramer, et al., 2007). In addition,
overexpression of EGFR is known to be more common in MIBC (Kassouf, et al., 2008). From
these facts, there is a possibility that EGFR-targeted therapies have the potential to improve
prognosis and survival in patients with MIBC.
On the other hand, there have been several reports that ErbB2 expression is not correlated with
any pathological features, including grade and stage or survival, in bladder cancer patients
(Jimenez, et al., 2001; Kassouf, et al., 2007). To explain this discrepancy in the research findings,
differences in patient backgrounds and evaluation methods have been suggested. The
differing reports show that there is no general agreement about the pathological significance
and prognostic role of the EGFR in patients with bladder cancer. Jimenez et al. made the
interesting observation that the frequencies of overexpression of ErbB2 in primary tumors and
in metastatic tumors were 37% and 63%, respectively (Jimenez, et al., 2001). This finding may
suggest that ErbB2 could be an effective therapeutic target for the inhibition of cancer cell
progression after treatment of primary tumors.
Gefitinib (brand name, Iressa) is a small molecular EGFR tyrosine kinase inhibitor that
selectively inhibits EGFR. Several clinical trials with gefitinib are now in progress. The results
of Cancer and Leukemia Group B (CALGB) study number 9012 showed 23 confirmed objective
responses (7 complete responses and 16 partial responses) in 54 assessable patients. The
median time to progression and overall survival were 7.4 months and 15.1 months, respec‐
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tively. Based on these results, the authors concluded that outcomes and survivals were not
significantly superior to those of previously reported results with GC alone (Philips et al.,
2009).However, there is a report that response rate and overall survival after combination
therapy with gefitinib and GC were similar to the rates using GC therapy alone in 54 chemo‐
therapy-naïve patients with locally advanced and metastatic urothelial cancer (Philips, et al.,
2009).
Cetuximab (Erbitux) is an intravenously administered monoclonal antibody against the EGFR.
In animal studies, cetuximab showed anti-growth activity against bladder cancer cells
(Perrotte, et al., 1999). Furthermore, the combination of paclitaxel and cetuximab exhibited
synergistic growth inhibition by suppression of proliferation and enhancement of apoptosis
in tumor and endothelial cells in a murine model of metastatic human bladder cancer (Inoue,
et al., 2000). Thus, cetuximab is expected to have a remarkable anti-tumor effect in patients
with advanced bladder cancer. A study comparing the effects of GC with or without cetuximab
in bladder cancer patients with locally advanced or metastatic disease is currently underway
in a phase II setting.
Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody to ErbB2 (HER2).
This drug has been reported to be safe and effective in other types of malignancies, especially
breast cancer (Burstein, et al., 2003). For treating bladder cancer, a phase II study of the effects
of second-line treatment with trastuzumab monotherapy in patients with metastatic urothelial
cancer and HER2 overexpression was completed in Germany (protocol number ML17599). In
addition, a multicenter phase II trial investigating trastuzumab together with paclitaxel,
carboplatin, and gemcitabine was conducted in 57 patients with advanced urothelial cancer
having positive expression of ErbB2 as determined by immunohistochemistry (CCUM-9955)
(Hussain, et al., 2007). This study showed a 70% response rate, and median times to progression
and survival were 9.3 months and 14.1 months, respectively. Interestingly, Trastuzumab is
being evaluated in combination with paclitaxel and radiotherapy as a bladder conservation
strategy.
Lapatinib is an oral small-molecule dual tyrosine kinase inhibitor of the EGFR and ErbB2. It
produces a remarkable response and anti-tumor effect in patients with urothelial cancer.
Synergic anti-tumor effects with various chemotherapy regimens are known to occur in
urothelial cancer cell lines (McHugh, et al., 2007). This phenomenon may enable reduced-dose
chemotherapy and/or reduced toxicity. On the other hand, a phase II study by Wulfing et al.
(2005) showed disappointing results in that only 2 out of 59 study patients showed partial
response when treated with lapatinib. Further studies and trials are necessary to obtain details
with regard to the optimal use and efficacy of lapatinib.
Erlotinib (Tarceva) is an oral small-molecule EGFR tyrosine kinase inhibitor. It has character‐
istics that inhibit activities of wild-type EGFR and mutant EGFRvIII without decreasing the
level of EGFR protein in a reversible manner (Zureikat and McLee, 2008). This agent has been
approved for metastatic non-small cell lung cancer and metastatic pancreatic cancer. In bladder
cancer, several clinical trials, including a phase II study, are exploring the use of erlotinib as a
prevention strategy or as neo-adjuvant therapy (NCT00749892).
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6.3. Vasculogenesis-related factors
Bevacizumab (Avastin) is a monoclonal antibody that acts as a VEGF inhibitor. It can bind all
VEGF isoforms. Bevacizumab is approved by the FDA for treating various solid tumors,
including colorectal cancer, breast cancer, and renal cell carcinoma. In urothelial cancer, a
phase II trial is being conducted on the use of cisplatin, gemcitabine and bevacizumab in
combination for metastatic urothelial cancer (Cancer: Hoosier Oncology Group, study number
GU04-75). A study by Hahn et al. (2011) showed that the best response, according to the
Response Evaluation Criteria in Solid Tumors, was complete response in 8 patients (19%) and
partial response in 23 patients (53%), out of 43 patients with metastatic or unresectable disease.
In addition, it showed that the median progression-free survival was 8.2 months, with a
median overall survival time of 19.1 months. Based on these results, these investigators
concluded that the full risk and benefit profile of this treatment in patients with metastatic
urothelial cancer will be determined by an ongoing phase III trial. In another study, phase II
trials are evaluating a neo-adjuvant GC regimen on the use of dose-dense (DD)-MVAC +
bevacizumab followed by radical cystectomy in patients with MIBC and patients with
resectable urothelial cancer of the bladder (NCT-00506155). An interesting pre-clinical trial
involving bevacizumab is being conducted, testing a combination of photodynamic therapy
(well-known as an emerging diagnostic and therapeutic strategy in bladder cancer [Patel, et
al., 2011]), bevacizumab, and fluorescence confocal endomicroscopy as a promising cancer
treatment approach (Bhuvaneswari, et al., 2010). A similar treatment strategy using a combi‐
nation of photodynamic therapy and molecular targeted therapy is being investigated by
another study group using bevaxizmab and cetuximab in a murine bladder cancer model
(Bhuvaneswari et al., 2011).
Thrombospondin (TSP)-1 is well-known as a representative molecule having anti-angiogenic
properties under physiological and pathological conditions. In bladder cancer, TSP-1 expres‐
sion has been negatively associated with malignant aggressiveness. (Grossfeld, et al., 2003).
This report also showed decreased expression of TSP-1 has been observed to predict poor
survival in patients with bladder cancer. Interestingly, these investigators also found that
alteration of p53 may decrease TSP-1 expression in bladder cancer. From these results, TSP-1
is speculated to be an effective and potential target for novel therapies. Actually, a plan for
TSP-1-target therapy has already been in existence and has been investigated in preclinical
studies, including a phase I trial (Taraboletti, et al., 2010; Li, et al., 2011). Unfortunately, such
a clinical trial is not being conducted in patients with MIBC.
7. Conclusions
In this paper, we described various trials and newly treatment strategies for patients with
MIBC. In present, choice of all or a part of operation, chemotherapy, and radiation therapy is
major treatment strategy for these patients. In addition, molecular-targeted therapy will be
added to these conventional therapies in near feature. However, many urologist, medical
oncologist, and radiation oncologists have a feeling that the near future strategies may not
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adequate to give satisfaction for outcome and survival in MIBC disease. So, numerous
investigators keep on studying the pathological features and molecular mechanism of bladder
cancer to break through the difficulty of the present strategies. We hope more detailed basic
studies and precise clinical trials in bladder cancer.
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